Recent events
Recent events tied to this brand in public sources.
Back to profile7 entries
2022
FDA approves Mylan's generic Symbicort
The U.S. FDA approved Mylan Pharmaceuticals' generic of Symbicort, described as the first FDA-approved generic of the medicine for asthma and COPD.
2021
Lawsuit over Xulane birth control patch
A patient sued Mylan Pharmaceuticals, Mylan Technologies, and Walgreen Co. over alleged product liability, negligence, breach of warranty, and failure to warn concerning the Xulane birth control patch. The article says the case was removed from an Illinois state court to federal court the previous Friday.
2021
Mylan sues Teva over alleged Copaxone competition restraints
Mylan Pharmaceuticals filed a federal lawsuit against Teva, alleging that Teva used tactics to delay competition for its multiple sclerosis drug Copaxone. The allegations are not presented as a court determination, and Teva had not yet responded.
2021
Kansas court rules substantially in Mylan's favor in EpiPen class action
The U.S. District Court for the District of Kansas ruled substantially in Mylan's favor on its summary judgment motion in a class action related to the EpiPen Auto-Injector. The court dismissed the plaintiffs' federal RICO claims and claims alleging that Mylan foreclosed branded competition through rebate arrangements. The court did not decide the remaining claim on its merits.
2020
Court enters summary judgment in Mylan's favor in Sanofi lawsuit
The U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the lawsuit brought by Sanofi over EpiPen products. Viatris characterized the court action as rejecting Sanofi's allegations of anticompetitive practices; the source reports a judgment, not a separate finding of misconduct.
2020
IICT partners with Mylan to test COVID-19 combination therapies
Hyderabad-based IICT partnered with Mylan's Indian subsidiary to test combination therapies for COVID-19; the article says trial sites were still to be identified and the application to conduct the trials had been submitted to India's drug controller.
2020
Mylan to acquire Aspen's European thrombosis portfolio
Mylan agreed to acquire Aspen's European thrombosis business for €641.9 million. The deal was expected to close before December 25, 2021; Aspen would continue manufacturing and supplying the drugs.